{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:39:14Z","timestamp":1773041954434,"version":"3.50.1"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastatic renal cell carcinoma (mRCC) is a common type of urologic malignancy with limited systemic treatment, especially for extensive metastatic lesions in the peritoneum and greater omentum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>A 35-year-old male patient was admitted to the hospital with left lumbar pain, leading to the discovery of left renal mass. He subsequently underwent a nephrectomy, with postoperative pathology confirming RCC. Following surgery, he received three cycles of interleukin-2 therapy. Within 5 months of nephrectomy, related examinations confirmed tumor recurrence and metastasis, and palliative surgery was performed. Postoperative pathology confirmed high-grade RCC, diagnosed as stage IV with pancreatic, adrenal, and splenic metastases. The patient then underwent first-line treatment with ICI (Immune Checkpoint Inhibitors) in combination with pezopanib for 9 months before progressing and then changing to second-line treatment with ICI in combination with axitinib for 2 months before progressing again. The patient was subsequently screened for clinical studies and rapidly progressed to extensive abdominal metastases after 1 month. The patient was then treated with bevacizumab abdominal artery perfusion embolization and achieved partial remission. Subsequent systemic therapy was changed to everolimus combined with voronib targeted therapy until now, and the lesion has continued to shrink on multiple follow-ups in between.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Abdominal arterial infusion of bevacizumab embolization provides a feasible local treatment option for peritoneal metastases in stage IV RCC, warranting further clinical exploration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1686650","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:48:35Z","timestamp":1773038915000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Intra-arterial infusion of bevacizumab for the treatment of peritoneal metastatic high-grade renal cell carcinoma: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Song","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Oncology, Wenzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University","place":["Wenzhou, Zhejiang, China"]},{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoming","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Wenzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomeng","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Wenzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jizhou","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Wenzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijia","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(01)00027-6","article-title":"Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases","volume":"41","author":"Ficarra","year":"2002","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.10.019","article-title":"First and second-line treatments in metastatic renal cell carcinoma","volume":"87","author":"Barragan-Carrillo","year":"2025","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.eururo.2004.02.002","article-title":"Changing concepts in the surgical management of renal cell carcinoma","volume":"45","author":"Lam","year":"2004","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2018.04.008","article-title":"Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group","volume":"98","author":"Meyer","year":"2018","journal-title":"Eur J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.06.017","article-title":"The role of stereotactic ablative body radiotherapy in renal cell carcinoma","volume":"82","author":"Ali","year":"2022","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"100674","DOI":"10.1016\/j.ctarc.2022.100674","article-title":"Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment","volume":"34","author":"Rigault","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1555","article-title":"Tumor microvessel density as a prognostic marker in high-risk renal cell carcinoma patients treated on ECOG-ACRIN E2805","volume":"24","author":"Jilaveanu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0774","article-title":"Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications","volume":"13","author":"Yao","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.186","article-title":"Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma","volume":"23","author":"Rini","year":"2005","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03435-6","article-title":"Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going","volume":"147","author":"D\u2019Amico","year":"2020","journal-title":"J Neurooncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat Rev Drug Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1686650\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:48:35Z","timestamp":1773038915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1686650\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":13,"alternative-id":["10.3389\/fimmu.2026.1686650"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1686650","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"article-number":"1686650"}}